Medtronic plc· MDT

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

• 

  Medtronic PLC $MDT Shares Purchased by AXQ Capital LP

  AXQ Capital LP lifted its position in shares of Medtronic PLC (NYSE: MDT) by 109.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 28,303 shares of the medical technology company's stock after purchasing an additional 14,816 shares during the quarter. AXQ Capital LP's holdings

  Sep 5, 2026
• 

  Medtronic executives to speak at upcoming investor conferences

  /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences:

  Sep 4, 2026
• 

  Medtronic executives to speak at upcoming investor conferences

  Medtronic executives to speak at upcoming investor conferences PR Newswire GALWAY, Ireland, Sept. 4, 2026

  Sep 4, 2026
• 

  4 Reasons to Buy Medtronic Stock Like There's No Tomorrow

  Medtronic's growth is accelerating again as its cardiovascular business expands. It's about to become a Dividend King, and its stock still looks like a bargain.

  Sep 3, 2026
• 

  Why Medtronic (MDT) is a Top Momentum Stock for the Long-Term

  Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

  Sep 3, 2026

• SN

  Medtronic price target raised to $95 from $80 at Stifel

  Stifel Nicolaus· Rick Wise· $95.00
  Sep 2, 2026
• TF

  Medtronic, Inc. (MDT) PT Raised to $99 at Truist Securities

  Truist Financial· Richard Newitter· $99.00
  Sep 2, 2026
• WF

  Medtronic, Inc. (MDT) PT Raised to $104 at Wells Fargo

  Wells Fargo· Larry Biegelsen· $104.00
  Sep 2, 2026
• MS

  Medtronic price target raised to $115 from $100 at Mizuho

  Mizuho Securities· Anthony Petrone· $115.00
  Sep 2, 2026
• UB

  UBS Upgrades Medtronic, Inc. (MDT) to Buy

  UBS· Priya Sachdeva· $100.00
  Jul 28, 2026